Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05286281 · ClinicalTrials.gov registry record · Phase 1
A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05286281 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 6 participants.
The verdict
NCT05286281, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the pharmacokinetics, excretion, mass balance and metabolism of PF-07265803 (formerly known as ARRY-371797) in approximately 6 healthy adult male participants.
Interventions
- DRUG PF-07265803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2022-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05286281
The ClinicalTrials.gov registry entry for NCT05286281 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-07265803 is the first listed.
NCT05286281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05286281 about?
NCT05286281 is a clinical study titled "A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803". The purpose of this study is to assess the pharmacokinetics, excretion, mass balance and metabolism of PF-07265803 (formerly known as ARRY-371797) in approximately 6 healthy adult male participants.
What is the current status of trial NCT05286281?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-03-31. Estimated completion is 2022-05-26.
What interventions are being tested in trial NCT05286281?
The interventions under investigation include: PF-07265803 (DRUG).
Who is sponsoring clinical trial NCT05286281?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.